Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2014 September;39(3) > Minerva Endocrinologica 2014 September;39(3):155-65

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

  GYNECOLOGICAL ENDOCRINOLOGY 

Minerva Endocrinologica 2014 September;39(3):155-65

Copyright © 2014 EDIZIONI MINERVA MEDICA

language: English

Endometriosis and ovarian cancer: clinical and molecular aspects

Pavlidou A. 1, Vlahos N. F. 1, 2

1 Second Department of Obstetrics and Gynecology, University of Athens Medical School, Aretaieion Hospital, Athens, Greece; 2 Department of Gynecology and Obstetrics, Johns Hopkins Hospital School of Medicine, Baltimore, MD, USA


PDF


Endometriosis is one of the most commonly encountered benign problems in gynecology. Even though endometriosis appears to predispose to ovarian cancer the progression from atypical epithelial proliferation (atypical endometriosis and metaplasia), to the formation of well-defined borderline tumors and finally to endometrioid ovarian cancer will take several years. To elaborate on the concept of endometriosis as a precursor of some types of ovarian cancer, we present an overview of the pathophysiological and genetic characteristics, common in those two conditions. Furthermore, we present the genetic mutations found in ovarian cancers and we outline the common genetic alterations of endometriosis and ovarian cancer, focusing on the PI3K/Akt/mTOR-signaling pathway.

top of page